Mizuho Forecasts Strong Price Appreciation for Veeva Systems (NYSE:VEEV) Stock

Key Points

• Mizuho raised Veeva Systems’ price target to $280 from $270 and maintained an “outperform” rating. The broader analyst consensus is “Moderate Buy,” with an average target of $281.
• Veeva reported strong fiscal second-quarter results, with revenue up 17.6% year over year to approximately $928 million and EPS of $2.35, beating analyst estimates. Management also raised fiscal 2027 guidance to about $3.7 billion in revenue and $9.21 EPS.
• Shares rose to $283.92 and trade at a premium valuation, with a P/E ratio above 50, making the stock vulnerable to slower growth or weaker AI adoption. The company also saw insider selling, while institutional investors own 88.2% of outstanding shares.

Veeva Systems (NYSE:VEEV - Get Free Report) had its target price lifted by Mizuho from $270.00 to $280.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the technology company's stock. Mizuho's price objective would indicate a potential downside of 1.38% from the stock's current price.

Several other equities analysts have also issued reports on VEEV. Oppenheimer upped their price objective on shares of Veeva Systems from $225.00 to $300.00 and gave the company an "outperform" rating in a research report on Monday, August 17th. BMO Capital Markets lifted their target price on Veeva Systems from $175.00 to $270.00 and gave the stock a "market perform" rating in a report on Thursday. BNP Paribas Exane reissued an "outperform" rating and issued a $285.00 target price on shares of Veeva Systems in a research note on Thursday, June 4th. UBS Group increased their price target on Veeva Systems from $190.00 to $290.00 and gave the stock a "neutral" rating in a report on Thursday. Finally, Evercore reaffirmed an "outperform" rating and set a $185.00 price target on shares of Veeva Systems in a research report on Thursday, June 4th. Nineteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $281.00.

Veeva Systems Stock Performance

VEEV traded up $39.01 during midday trading on Thursday, reaching $283.92. 3,880,602 shares of the company were exchanged, compared to its average volume of 2,462,877. The stock has a market capitalization of $46.12 billion, a P/E ratio of 50.48, a PEG ratio of 1.06 and a beta of 0.92. Veeva Systems has a one year low of $148.05 and a one year high of $310.50. The stock's 50-day simple moving average is $203.41 and its 200 day simple moving average is $183.04.

Veeva Systems (NYSE:VEEV - Get Free Report) last announced its quarterly earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating analysts' consensus estimates of $2.22 by $0.13. Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. The business had revenue of $927.96 million for the quarter, compared to the consensus estimate of $905.38 million. During the same period last year, the company posted $1.99 EPS. Veeva Systems's revenue for the quarter was up 17.6% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, research analysts anticipate that Veeva Systems will post 6.65 earnings per share for the current year.

Insider Activity at Veeva Systems

In other news, insider Thomas D. Schwenger sold 36,000 shares of the company's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the completion of the transaction, the insider directly owned 19,449 shares of the company's stock, valued at $4,866,723.27. This represents a 64.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Veeva Systems

Several institutional investors have recently bought and sold shares of the company. Empire Life Investments Inc. lifted its holdings in Veeva Systems by 21.1% during the 4th quarter. Empire Life Investments Inc. now owns 37,054 shares of the technology company's stock worth $8,272,000 after purchasing an additional 6,453 shares during the last quarter. Czech National Bank bought a new stake in Veeva Systems in the 2nd quarter valued at $7,584,000. BNP Paribas boosted its stake in Veeva Systems by 89.3% in the 4th quarter. BNP Paribas now owns 19,239 shares of the technology company's stock valued at $4,308,000 after purchasing an additional 9,077 shares during the period. ABN Amro Investment Solutions grew its holdings in Veeva Systems by 28.4% in the 4th quarter. ABN Amro Investment Solutions now owns 76,809 shares of the technology company's stock valued at $17,146,000 after buying an additional 17,007 shares in the last quarter. Finally, AustralianSuper Pty Ltd acquired a new position in Veeva Systems in the 4th quarter valued at $2,453,000. Institutional investors own 88.20% of the company's stock.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Fiscal Q2 revenue rose 17.6% year over year to approximately $928 million, exceeding the $905.4 million analyst consensus. Adjusted earnings of $2.35 per share also surpassed expectations of $2.22 and increased from $1.99 in the prior-year quarter. Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock Up
• Positive Sentiment: Management raised fiscal 2027 guidance to approximately $3.7 billion in revenue and $9.21 in earnings per share, above consensus estimates of about $3.6 billion and $8.58, respectively. Third-quarter revenue guidance of $932 million to $935 million and EPS guidance of $2.33 to $2.34 also exceeded analyst expectations. Veeva Announces Fiscal 2027 Second Quarter Results
• Positive Sentiment: Strong Vault CRM execution, including a record quarter, supported confidence that Veeva can maintain more than 70% market share. Falcon AI demand is building, with the company expecting its first customer go-lives this year. Veeva Targets Maintaining CRM Share as Falcon Go-Lives Begin
• Positive Sentiment: Several analysts lifted their price targets following the results. RBC raised its target to $325 and kept an outperform rating, while Barclays raised its target to $315 with an overweight rating. Guggenheim and Truist also raised targets to $310 and $305, respectively.
• Neutral Sentiment: Other analysts remained cautious despite raising targets: UBS set a $290 target with a neutral rating, Canaccord set $260 with a hold rating, and Morgan Stanley set $275 with an equal-weight rating. These targets indicate that some firms view much of the earnings optimism as already reflected in the stock.
• Negative Sentiment: At a roughly 50.8 forward? P/E ratio as reported, Veeva carries a premium valuation, leaving the shares sensitive to any slowdown in growth, weaker AI adoption, or future guidance disappointments.

Veeva Systems Company Profile

Veeva Systems NYSE: VEEV is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva's product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source